Enhancer of zeste homolog 2 (EZH2), a key component of the polycomb repressor complex (PRC) 2 which mediates histone H3 methylation at lysine 27 (H3K27), has been linked to aggressive progression of breast and prostate cancers [43,44]. Here, EZH2 is linked to prostate carcinoma.